Evidence map›Paper›PMID 41441969›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026

Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study.

Semiu O Gbadamosi, David Shi, Abdalla Aly, Caichen K Zhong, Husam Albarmawi, Aidan McGovern, Anthony Hoovler, Carlos Campos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Semiu O GbadamosiReal-World Evidence, Clinical Data Science and Evidence, Novo Nordisk Inc., 800 Scudders Mill Rd, Plainsboro, NJ, 08536, USA.
David ShiReal-World Evidence, Clinical Data Science and Evidence, Novo Nordisk Inc., 800 Scudders Mill Rd, Plainsboro, NJ, 08536, USA.
Abdalla AlyReal-World Evidence, Clinical Data Science and Evidence, Novo Nordisk Inc., 800 Scudders Mill Rd, Plainsboro, NJ, 08536, USA. VAAY@novonordisk.com.
Caichen K ZhongReal-World Evidence, Clinical Data Science and Evidence, Novo Nordisk Inc., 800 Scudders Mill Rd, Plainsboro, NJ, 08536, USA.
Husam AlbarmawiReal-World Evidence, Clinical Data Science and Evidence, Novo Nordisk Inc., 800 Scudders Mill Rd, Plainsboro, NJ, 08536, USA.
Aidan McGovernHEOR Evidence Strategy and Synthesis, Clinical Data Science and Evidence, Novo Nordisk Inc., Plainsboro, NJ, USA.
Anthony HoovlerMedical Affairs, Novo Nordisk Inc., Plainsboro, NJ, USA.
Carlos CamposDepartment of Family Medicine, University of Texas Health Science Center, San Antonio, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough there is a recognized negative interplay between metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes (T2D), the extent to which comorbid MASH exacerbates T2D complications is not well understood. This real-world cohort study evaluated whether the coexistence of these diseases is associated with increased risk of microvascular and macrovascular complications.

methodsWe identified eligible adults with T2D from the Optum

resultsThe study comprised 7396 and 6207 matched pairs in the microvascular and macrovascular complications cohorts, respectively. In this T2D population, mean (standard deviation) follow-up was 2.8 (2.0) years for patients with MASH and 2.4 (1.8) years for patients without MASH in both cohorts. Compared with patients with T2D without MASH, those with T2D and MASH had increased hazards of microvascular (sHR 1.19 [95% confidence interval (CI) 1.12-1.26]) and macrovascular complications (sHR 1.15 [95% CI 1.08-1.23]). A similar trend was observed for the stratified subgroup analyses.

conclusionPatients with T2D and MASH had higher hazards of microvascular and macrovascular complications versus those with T2D without MASH. These findings suggest that the presence of MASH accelerates T2D-related complications, creating a clinical imperative for integrated screening and management approaches to identify this high-risk population among patients with T2D.

Indexed as

Macrovascular complicationsMetabolic dysfunction-associated steatohepatitis (MASH)Microvascular complicationsType 2 diabetes

Identifiers

PMID41441969
PMCPMC12909725

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.